Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China | Zendy

Yilong Wang | Zendy; Xiaoling Liao | Zendy; Xingquan Zhao | Zendy; David Z. Wang | Zendy; Chunxue Wang | Zendy; Mai N. NguyenHuynh | Zendy; Yong Zhou | Zendy; Liping Liu | Zendy; Xianwei Wang | Zendy; Gaifen Liu | Zendy; Hao Li | Zendy; Yongjun Wang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Using Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke in China

Author(s) -

Yilong Wang,

Xiaoling Liao,

Xingquan Zhao,

David Z. Wang,

Chunxue Wang,

Mai N. NguyenHuynh,

Yong Zhou,

Liping Liu,

Xianwei Wang,

Gaifen Liu,

Hao Li,

Yongjun Wang

Publication year - 2011

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.110.604249

Subject(s) - medicine , interquartile range , emergency department , recombinant tissue plasminogen activator , stroke (engine) , thrombolysis , emergency medicine , tissue plasminogen activator , ischemic stroke , surgery , ischemia , modified rankin scale , myocardial infarction , mechanical engineering , psychiatry , engineering

Little is known about intravenous recombinant tissue plasminogen activator (rtPA) use in China. By accessing the Chinese National Stroke Registry (CNSR), the rate of intravenous rtPA use was reviewed. We specifically examined the issues of prehospital and in-emergency department delay and compared them with the published data from developed countries.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research